Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALAD | P13716 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505511 | 0.88 | ALAD (0.70) | ALADHDAC6DAOMEN1POLB | |
| SCHEMBL3641638 | 0.87 | HSD17B1 (0.59) | ALADHDAC6DAOHSD17B1HSD17B2 | |
| SCHEMBL6451881 | 0.86 | ALAD (0.68) | ALADHDAC6DAOMEN1RAB9A | |
| SCHEMBL13376205 | 0.86 | DAO (0.55) | ALADHDAC6DAOKMOHSD17B1 | |
| SCHEMBL3638317 | 0.83 | ALAD (0.51) | ALADHDAC6KMO | |
| SCHEMBL4153715 | 0.79 | ABL1 (0.51) | ALADHDAC6RAB9AKMO | |
| SCHEMBL28875556 | 0.77 | KDM4E (0.51) | HDAC6RAB9AHSD17B1HSD17B2MMP12 | |
| SCHEMBL4385980 | 0.77 | DYRK1A (0.60) | ALADHDAC6RAB9AKMO | |
| SCHEMBL4381926 | 0.76 | ALAD (0.66) | ALADHDAC6DAOMMP12 | |
| SCHEMBL6450949 | 0.76 | ALAD (0.71) | ALADHDAC6DAOMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | ALAD 2339/4885HDAC6 2875/4885DAO 144/4885 |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | ALAD 2339/4885HDAC6 2875/4885DAO 144/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | ALAD 2339/4885HDAC6 2875/4885DAO 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.